Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00004029 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004029 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer |
| Official title | A PHASE I TRIAL OF RECOMBINANT VACCINIA VIRUS THAT EXPRESSES PSA IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | recombinant viral vaccine therapy, sargramostim |
| Enrollment | 46 |
| Start date | Dec 1, 1996 |
| Primary completion | May 1, 2006 |
| First posted | Aug 30, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: